ReviewCurrent opinion in immunology2018
IL-6: a cytokine at the crossroads of autoimmunity.
Review in Current opinion in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed.
- Repurposing FDA approved drugs targeting IL-6 associated signalling for the management of rheumatoid arthritis: an in silico and experimental approach.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Investigating the role of serum IL-6 in predicting outcomes of b-cell depleting therapy in multiple sclerosis: a retrospective cohort study.BMC neurology · 2026Article
- Immunopathological Profile of Patients with Thymic Epithelial Tumour and Good Syndrome in Advanced Stage.Journal of clinical immunology · 2026Article
- Evaluating immunoreactivity of hybridoma-derived antibody mixtures generated against AU-565 cell line for diagnosis and immunotherapy of breast cancer.BMC cancer · 2026Article
- The Prognostic Value of Inflammatory Markers in Paediatric Acute Kidney Injury.Journal of clinical medicine · 2026Article
- Exploring the oncogenic mechanism of plasmacytoma variant translocation 1 (PVT1) gene in solid cancers; emphasis on microRNA regulation pathways.Cancer cell international · 2026Review
- An integrative analysis of genetic factors reveals dysregulation of cytokines, immune signaling, and T cell activity as the underlying immune mechanisms in autoimmune immune thrombocytopenia.Thrombosis journal · 2026Article
- Role of Interleukin-6 in Atherothrombosis and Myocardial Infarction.Current atherosclerosis reports · 2026Review
- Serum HDL subfractions are impaired by COVID-19 vaccine in patients with thymic epithelial tumors.Scientific reports · 2026Article
- A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive decline.Frontiers in immunology · 2026Article
- HE4: a potential diagnostic biomarker in autoimmune diseases.Central-European journal of immunology · 2026Review
- Severity and 28-day in-hospital mortality of interleukin-6, neutrophil to lymphocyte ratio, and APACHE II score in patients with sepsis.Frontiers in cellular and infection microbiology · 2026Article
- Review
- Role of Myokines on the Bone Metabolism of Craniofacial Region: A Scoping Review.Dentistry journal · 2025Review
- Epigenetic mechanisms underlying variation of IL-6, a well-established inflammation biomarker and risk factor for cardiovascular disease.Atherosclerosis · 2025Article
- Advances in understanding the role of interleukins in pulmonary fibrosis (Review).Experimental and therapeutic medicine · 2025Review
- Defining a novel DYRK1A-gp130/IL-6R-pSTAT axis that regulates Th17 differentiation.ImmunoHorizons · 2025Article
- Targeted immunotherapies for Graves' thyroidal & orbital diseases.Frontiers in immunology · 2025Review
- IL-6 and CD4Journal of inflammation research · 2025Article
- Comparative risk of systemic autoimmune diseases in juvenile idiopathic arthritis treated with TNF-α or IL-6 inhibitors: a real-world cohort study.Frontiers in immunology · 2025Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
IL-6 is implicated in the development and progression of autoimmune diseases in part by influencing CD4 T cell lineage and regulation. Elevated IL-6 levels drive inflammation in a wide range of autoimmune diseases, some of which are also characterized by enhanced T cell responses to IL-6. Notably, the impact of IL-6 on inflammation is contextual in nature and dependent on the cell type, cytokine milieu and tissue. Targeting the IL-6/IL-6R axis in humans has been shown to successfully ameliorate a subset of autoimmune conditions. In this review, we discuss recent studies investigating how IL-6 regulates the CD4 T cell response in the context of autoimmune disease and highlight how blocking different aspects of the IL-6 pathway is advantageous in the treatment of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.